Business ❯ Biotechnology ❯ Clinical Research

Drug Development

Regulatory Affairs Therapeutics Phase 3 Trials EIK1001 Investor Relations Protara Therapeutics Wave Life Sciences Investments in Healthcare

Atrogi Begins Dosing in 8-Week Human Study of GRK2-Biased β2 Agonist ATR-258

The investigator-led trial will probe how the next-generation modulator influences human skeletal muscle to guide development.

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering

Protara Reports Strong Interim Phase 2 Results for TARA-002 in Pediatric Lymphatic Malformations

Rapport Seizure Drug Posts Strong Phase 2 Signal as Company Plans Phase 3